Exploring the neurobiological mechanisms of ketamine, psychedelics, and other rapid antidepressants
The recent development of novel, fast acting, and durable antidepressant treatments such as Ketamine, Brexanolone, and Psilocybin has disrupted our view of the neuroscience and treatment of mood disorders. Our focus is research into the basic and translational science of how these drugs work.
Anyone interested is welcome to participate!
When: 3rd Monday of the month, 3:00p
Where: HYBRID: Couch Building 2nd floor conference room (Medical Campus) and Zoom
Organizer: Joshua Siegel (Resident, WashU Psychiatry)
Note that individual events are listed on the ONR Calendar.
2022/2023 Schedule
For inquiries contact Joshua Siegel.
July 18, 2022
Amelia Christensen (Kepecs lab, WashU Neuroscience)
“Interactions between psychedelic agonism of 5ht2a receptors and dopamine dependent reinforcement learning”
August 15, 2022
NOTE 3:00p start time
Rick Reneau (Braver lab, WashU Psychological & Brain Sciences)
“Imaging the effect of ketamine on synaptic density (SV2A) in the living brain” Molecular Psychiatry (2022)
September 19, 2022
Oliver Krentzman (Kepecs lab, WashU Neuroscience)
“Oxytocin-dependent reopening of a social reward learning critical period with MDMA” (Nature 2019)
October 17, 2022
Peter Lambert (Mennerick lab, WashU Psychiatry)
“Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2” (Neuron 2022)
November 21, 2022
Joshua Siegel (Nicol lab, WashU Psychiatry)
Jonah Padawer-Curry (Bauer lab, WashU Radiology)
WiP: “Neural and neurovascular effects of 5-HT2A receptor modulation (psychedelic, non-psychedelic agonism, and antagonism)”
